$2.49T
Total marketcap
$75.71B
Total volume
BTC 50.56%     ETH 15.05%
Dominance

Cybin Inc. CYBN.NE Stock

0.5 CAD {{ price }} -3.846150% {{change_pct}}%
COUNTRY
Canada
Exchange
Cboe CA
Market Cap
395.06M CAD
LOW - HIGH [24H]
0.49 - 0.54 CAD
VOLUME [24H]
393.03K CAD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.3 CAD

Cybin Inc. Price Chart

Cybin Inc. CYBN.NE Financial and Trading Overview

Cybin Inc. stock price 0.5 CAD
Previous Close 0.32 CAD
Open 0.33 CAD
Bid 0.33 CAD x 0
Ask 0.36 CAD x 0
Day's Range 0.33 - 0.37 CAD
52 Week Range 0.3 - 1.5 CAD
Volume 318.21K CAD
Avg. Volume 101.68K CAD
Market Cap 69.03M CAD
Beta (5Y Monthly) 1.88952
PE Ratio (TTM) N/A
EPS (TTM) -0.3 CAD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

CYBN.NE Valuation Measures

Enterprise Value 40.38M CAD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 1.2203391
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.749

Trading Information

Cybin Inc. Stock Price History

Beta (5Y Monthly) 1.88952
52-Week Change -57.33%
S&P500 52-Week Change 20.43%
52 Week High 1.5 CAD
52 Week Low 0.3 CAD
50-Day Moving Average 0.42 CAD
200-Day Moving Average 0.58 CAD

CYBN.NE Share Statistics

Avg. Volume (3 month) 101.68K CAD
Avg. Daily Volume (10-Days) 133.07K CAD
Shares Outstanding 191.76M
Float 156.66M
Short Ratio N/A
% Held by Insiders 22.28%
% Held by Institutions 7.86%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End March 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -43.43%
Return on Equity (ttm) -71.33%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -53938000 CAD
Net Income Avi to Common (ttm) -51867000 CAD
Diluted EPS (ttm) -0.3
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 22.64M CAD
Total Cash Per Share (mrq) 0.12 CAD
Total Debt (mrq) 0 CAD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 6.891
Book Value Per Share (mrq) 0.295

Cash Flow Statement

Operating Cash Flow (ttm) -46314000 CAD
Levered Free Cash Flow (ttm) -32884624 CAD

Profile of Cybin Inc.

Country Canada
State ON
City Toronto
Address 100 King Street West
ZIP M5X 1C9
Phone N/A
Website https://www.cybin.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 50

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Q&A For Cybin Inc. Stock

What is a current CYBN.NE stock price?

Cybin Inc. CYBN.NE stock price today per share is 0.5 CAD.

How to purchase Cybin Inc. stock?

You can buy CYBN.NE shares on the Cboe CA exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cybin Inc.?

The stock symbol or ticker of Cybin Inc. is CYBN.NE.

Which industry does the Cybin Inc. company belong to?

The Cybin Inc. industry is Biotechnology.

How many shares does Cybin Inc. have in circulation?

The max supply of Cybin Inc. shares is 790.12M.

What is Cybin Inc. Price to Earnings Ratio (PE Ratio)?

Cybin Inc. PE Ratio is now.

What was Cybin Inc. earnings per share over the trailing 12 months (TTM)?

Cybin Inc. EPS is -0.3 CAD over the trailing 12 months.

Which sector does the Cybin Inc. company belong to?

The Cybin Inc. sector is Healthcare.